Growth Metrics

West Pharmaceutical Services (WST) Total Debt (2016 - 2026)

West Pharmaceutical Services has reported Total Debt over the past 18 years, most recently at $202.8 million for Q1 2026.

  • Quarterly Total Debt changed 0.1% to $202.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $202.8 million through Mar 2026, changed 0.1% year-over-year, with the annual reading at $202.8 million for FY2025, 0.1% changed from the prior year.
  • Total Debt was $202.8 million for Q1 2026 at West Pharmaceutical Services, roughly flat from $202.8 million in the prior quarter.
  • Over five years, Total Debt peaked at $210.5 million in Q1 2022 and troughed at $72.8 million in Q4 2023.
  • The 5-year median for Total Debt is $202.7 million (2025), against an average of $179.1 million.
  • Peak annual rise in Total Debt hit 178.3% in 2024, while the deepest fall reached 65.05% in 2024.
  • Tracing WST's Total Debt over 5 years: stood at $206.7 million in 2022, then tumbled by 64.78% to $72.8 million in 2023, then skyrocketed by 178.3% to $202.6 million in 2024, then grew by 0.1% to $202.8 million in 2025, then changed by 0.0% to $202.8 million in 2026.
  • According to Business Quant data, Total Debt over the past three periods came in at $202.8 million, $202.8 million, and $202.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.